CA-VISA-INC.
6.12.2018 14:02:22 CET | Business Wire | Press release
Visa (NYSE:V), the Official Payment Services Partner of FIFA, has announced partnerships with the Union of European Football Associations’ (UEFA) Women’s Football Competitions and the Confederation of African Football (CAF) Total Africa Cup of Nations tournament to evolve its sponsorship portfolio and connect with fans around the world. Leveraging its sponsorship expertise and success at the 2018 FIFA World Cup Russia™, Visa will implement its innovative payment technology at the tournament venues and deliver exclusive experiences for cardholders and clients. By tapping into the strength of the Visa brand and its influential role for fans in football, Visa will help to further elevate women’s football and these regional tournaments.
“Visa has strategically positioned itself at the center of football and these events will further exemplify the unique experiences only Visa can provide to fans across the globe,” said Chris Curtin, chief brand and innovation marketing officer, Visa Inc. “These tournaments allow us distinctive opportunities to showcase Visa’s payment innovation, strengthen partnerships and highlight our evolved offerings to clients and fans.”
Expanding Global Football Portfolio
Visa is partnering with the UEFA Women’s Football Competitions through 2025 to continue its efforts to inspire and empower women, as women’s football continues to grow at all levels. Through its partnership, Visa will collaborate with UEFA for the 2021 Women’s European Championships in the United Kingdom and the annual Women’s Champions League beginning in 2019. Complementing the national team tournament with the world’s finest club competition allows Visa to be at the center of women’s football and strengthens its efforts around diversity, acceptance, and inclusion leading up to the FIFA Women's World Cup France 2019™.
Visa also announced its partnership with CAF as a sponsor of the Total Africa Cup of Nations (AFCON) tournament in 2019 and 2021. The deal will make Visa the exclusive payment services provider at all venues and the official partner of the player escort program. With CAF, Visa will be able to capitalize on football’s popularity throughout the continent, tap into high-growth markets and continue to deliver exclusive benefits to its local communities, clients, partners and fans as they come together to support the best of African football.
Driving Innovation around the Fan Experience
Visa, a FIFA partner since 2007, continues to drive toward new payment innovation that provides fans with faster and enhanced experiences at checkout. Whether it be remote and mobile ticket purchasing, contactless payment technology at transit locations, in-seat ordering or new ways to pay for retail, Visa will utilize its transit, retail and commerce expertise to deliver innovative payments that reimagine the fan experience.
These tournaments present an opportunity for the brand to build upon its success of 2018 FIFA World Cup Russia™. Visa brought contactless payment technology to 12 tournament stadiums and curated unforgettable experiences for more than 250 clients and 3,000 consumers who traveled from over a hundred different countries. In 103 markets around the world, Visa partnered with more than 500 issuers and 40 merchants in 24 languages on a variety of FIFA-related activities, whether to run custom marketing programs, host in-market viewing parties or utilize Visa’s exclusive marketing campaign assets to drive mutual business priorities.
FIFA Women's World Cup France 2019™ Ticket Presale for Visa Cardholders
Following the FIFA Women's World Cup France 2019™ Draw on December 8, Visa will offer an exclusive opportunity for cardholders to be the first fans to purchase individual match tickets for the tournament. The exclusive presale phase will take place from December 10 through December 23 and tickets for all matches will be available. FIFA recently announced that 150,000 FIFA Women's World Cup France 2019™ tickets have been sold since package sales opened in September.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , https://usa.visa.com/visa-everywhere/blog.html and @VisaNews .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005237/en/
Contact:
Visa Inc. Sheerin Salimi shesalim@visa.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom